Ultragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($1.72), $0.01 better than the analyst estimate of ($1.73).

Cash, cash equivalents, and investments were $457.5 million as of June 30, 2017.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.